Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 3/20 | 0.45 |
| ▸ | CA1 | P00915 | 3/20 | 0.45 |
| ▸ | CA2 | P00918 | 3/20 | 0.45 |
| ▸ | CA9 | Q16790 | 3/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29774471 | 0.89 | TDP1 (0.49) | TDP1ALDH1A1MEN1KMT2AGAA | |
| SCHEMBL15341660 | 0.89 | TDP1 (0.61) | TDP1ALDH1A1MEN1KMT2AGAA | |
| SCHEMBL1082707 | 0.86 | TDP1 (0.56) | TDP1ALDH1A1MEN1KMT2AGAA | |
| SCHEMBL22672290 | 0.85 | TDP1 (0.67) | TDP1MEN1KMT2AGAAHTT | |
| SCHEMBL1894118 | 0.84 | TDP1 (0.47) | TDP1ALDH1A1MEN1KMT2AGAA | |
| SCHEMBL15326216 | 0.83 | ALDH1A1 (0.47) | TDP1ALDH1A1MEN1KMT2AGAA | |
| SCHEMBL3341020 | 0.83 | TDP1 (0.67) | TDP1ALDH1A1MEN1KMT2AGAA | |
| SCHEMBL21600761 | 0.82 | TDP1 (0.53) | TDP1ALDH1A1MEN1KMT2AGAA | |
| SCHEMBL30112571 | 0.81 | TDP1 (0.51) | TDP1ALDH1A1MEN1KMT2AGAA | |
| SCHEMBL5209522 | 0.81 | TDP1 (0.51) | TDP1ALDH1A1MEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3750887-B1 | BIARYL DERIVATIVES AND THEIR PHARMACEUTICAL APPLICATION FOR THE TREATMENT OF PD-1/PD-L1 SIGNAL PATHWAY-MEDIATED DISEASES | ABBISKO THERAPEUTICS CO LTD (CN) | 2025-05-28 | — | — | EP | disclosed |
| CN-116848113-A | Bicyclic compounds as HPK1 inhibitors and application thereof | 南京再明医药有限公司 | 2023-10-03 | — | — | CN | disclosed |
| WO-2023178299-A1 | PRODRUGS OF GANAXOLONE | MARINUS PHARMACEUTICALS, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| US-20230152698-A1 | POSITIVE RESIST COMPOSITION AND PATTERN FORMING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-05-18 | — | — | US | disclosed |
| US-11459339-B2 | Biaryl derivative, preparation method thereof and pharmaceutical application thereof | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2022-10-04 | — | — | US | disclosed |
| EP-3585774-B1 | NOVEL SUBSTITUTED SULFOXIMINE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME (US) | 2021-11-10 | — | — | EP | disclosed |
| US-20200060273-A1 | FUNGICIDAL COMPOSITIONS | NOVUS INTERNATIONAL, INC. | 2020-02-27 | — | — | US | disclosed |
| WO-2019149183-A1 | BIARYL DERIVATIVE, PREPARATION METHOD THEREOF AND PHARMACEUTICAL APPLICATION THEREOF | 上海和誉生物医药科技有限公司 | 2019-08-08 | — | — | WO | disclosed |
| WO-2019020828-A9 | NOVEL FUNCTIONALIZED PURINE-2,6-DIONES AND THEIR USE IN MEDICINE | THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING (SE) | 2019-04-11 | — | — | WO | disclosed |
| WO-2019020828-A1 | NOVEL FUNCTIONALIZED PURINE-2,6-DIONES AND THEIR USE IN MEDICINE | THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING (SE) | 2019-01-31 | — | — | WO | disclosed |
| US-7244721-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2007-07-17 | — | — | US | disclosed |
| US-20070142373-A1 | Quinoline derivatives as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-06-21 | — | — | US | disclosed |
| US-20070142373-A1 | Quinoline derivatives as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-06-21 | — | — | US | disclosed |
| US-20070049570-A1 | Quinoline derivatives as phosphodiesterase inhibitors | DEAN ANTHONY W | 2007-03-01 | — | — | US | disclosed |
| US-20070049570-A1 | Quinoline derivatives as phosphodiesterase inhibitors | DEAN ANTHONY W | 2007-03-01 | — | — | US | disclosed |
| US-7183276-B2 | Azole compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-27 | — | — | US | disclosed |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION CORVAS INTERNATIONAL, LTD. | 2007-02-08 | — | — | US | disclosed |
| US-20050090534-A1 | Azole compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-04-28 | — | — | US | disclosed |
| EP-1486490-A1 | AZOLE COMPOUNDS | Takeda Chemical Industries, Ltd. (JP) | 2004-12-15 | — | — | EP | disclosed |
| WO-2004103998-A1 | QUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090534-A1 | Azole compounds | AHR, NR0B2, NR2C2 | TDP1 4271/4885ALDH1A1 1651/4885MEN1 1626/4885 |
| US-20200060273-A1 | FUNGICIDAL COMPOSITIONS | ERG28, CYP51A1, CYP19A1 | TDP1 1139/4885ALDH1A1 1213/4885MEN1 1189/4885 |
| US-11459339-B2 | Biaryl derivative, preparation method thereof and pharmaceutical application thereof | PDCD1, PDCD1LG2, CD274 | TDP1 3068/4885ALDH1A1 281/4885MEN1 3519/4885 |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | TDP1 3248/4885ALDH1A1 2369/4885MEN1 4495/4885 |
| US-20070049570-A1 | Quinoline derivatives as phosphodiesterase inhibitors | PDE3B, PDE4B, PDE4A | TDP1 70/4885ALDH1A1 623/4885MEN1 2927/4885 |
| US-20070142373-A1 | Quinoline derivatives as phosphodiesterase inhibitors | PDE3B, PDE4B, PDE4A | TDP1 70/4885ALDH1A1 623/4885MEN1 2927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.